Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

Background/Aim. Hormone suppression therapy is used in men with advanced prostate cancer improving chances of longer survival. The aim of this study was to investigate the influence of androgen blockades on testosterone and luteinizing hormone (LH) values in patients with locally advanced and me...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vojinov Saša, Levakov Ivan, Jeremić Dimitrije, Živojinov Srđan, Marušić Goran
Format:	Article
Language:	English
Published:	Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade 2011-01-01
Series:	Vojnosanitetski Pregled
Subjects:	prostatic neoplasms androgen antagonists luteinizinghormone testosterone prostate-specific antigen
Online Access:	http://www.doiserbia.nb.rs/img/doi/0042-8450/2011/0042-84501104321V.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adenocarcinoma of the prostate with small cell component and low levels of prostate specific antigen
by: Vojinov Saša, et al.
Published: (2020-01-01)

Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia
by: Trivunić-Dajko Sandra, et al.
Published: (2020-01-01)

Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer
by: L. V. Spirina, et al.
Published: (2019-04-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

The Combination of Curcumae Radix and Syzygium Aromaticum Extracts Mitigates Benign Prostatic Hyperplasia through Anti-Proliferative and Anti-Inflammatory Effects
by: Geum Hwa Lee, et al.
Published: (2025-07-01)

Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients
by: Gede Wirya Kusuma Duarsa, et al.
Published: (2021-07-01)

Advanced prostatic carcinomas with low serum levels of prostate-specific antigen
by: Cerović Snežana J., et al.
Published: (2002-01-01)

The impact of exercise on prostate-specific antigen and testosterone in prostate cancer: a systematic review and meta-analysis
by: Fuxun Zhang, et al.
Published: (2025-12-01)

Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post‐Randomization Analysis
by: Sayeh Fattahi, et al.
Published: (2025-08-01)

New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy
by: Pedro Henrique Isaacsson Velho, et al.
Published: (2018-04-01)

Androgens and severity of the new coronavirus infection course
by: A. A. Gritskevich, et al.
Published: (2022-06-01)

Relationship between serum Prostate Specific Antigen (PSA) in women with polycystic ovary syndrome and some reproductive hormones in Kirkuk city
by: Marwa Ghazi Rifatt, et al.
Published: (2023-02-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

Optimal use of prostate specific antigen for prostate cancer screening
by: Miočinović Ranko, et al.
Published: (2013-01-01)

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
by: Tae Hwan Kim, et al.
Published: (2023-11-01)

Androgen receptor inhibitors in treating prostate cancer
by: Ryan N Cole, et al.
Published: (2025-03-01)

Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies
by: Reshmi Shrestha, et al.
Published: (2022-03-01)

Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
by: Patricia Tai, et al.
Published: (2025-07-01)

Neuroendocrine differentiation in prostate cancer
by: Cerović Snežana J., et al.
Published: (2004-01-01)

The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review
by: Renee E. Vickman, et al.
Published: (2020-07-01)

Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
by: Ze Wang, et al.
Published: (2025-08-01)

Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer
by: Changde Fu, et al.
Published: (2025-03-01)

Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
by: Minseok Suh, et al.
Published: (2024-03-01)

Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
by: Jae Heon Kim, et al.
Published: (2025-01-01)

Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review
by: Alan de J. Martinez-Salas, et al.
Published: (2021-07-01)

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer
by: Allison B. Reiss, et al.
Published: (2024-10-01)

Prospective validation study of a combined urine and plasma test for predicting high-grade prostate cancer in biopsy naïve men
by: Torben Brøchner Pedersen, et al.
Published: (2025-01-01)

Estimation of Testosterone, Estradiol and some Markers in Sera of Iraqi Patients with Benign Prostatic Hyperplasia.
by: Baghdad Science Journal
Published: (2013-12-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

The Prostate Problem You Can’t Put Your Finger on the Normal Way: A Case of Perineal Prostate Cancer Post Transperineal Prostate Biopsy
by: Kevin Yinkit Zhuo, et al.
Published: (2023-05-01)

A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer
by: Pongwut Danchaivijitr, et al.

Molecular Perspectives on Prostate Cancer: The Role of microRNAs in Androgen Receptor Regulation
by: Asbiel Felipe Garibaldi-Ríos, et al.
Published: (2024-11-01)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)

Characterisation of Multiparametric Magnetic Resonance Imaging of the Prostate in Younger Men with Normal Prostate-specific Antigen Within the PROBASE Study
by: Rouvier Al-Monajjed, et al.
Published: (2025-05-01)

Transperineal US-Guided Biopsy in Metastatic Prostate Cancer with Low Prostate Specific Antigen: A Case Report
by: Seongeun Jung, et al.
Published: (2025-05-01)

Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour volume)
by: Antonio B. Porcaro, et al.
Published: (2016-01-01)

Metastatic bone lesions of men in combination with an increase in serum PSA from the point of view of diagnosing carcinomas of unknown primary localization
by: O. V. Poslavska, et al.
Published: (2019-05-01)

Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer
by: Ahamed Y, et al.
Published: (2025-08-01)

The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy
by: Heikki Seikkula, et al.
Published: (2024-11-01)

Divergent androgen regulation of unfolded protein response pathways drives prostate cancer
by: Xia Sheng, et al.
Published: (2015-04-01)